Media & Publications

PepGen to Present Late-Breaking Data from Novel Enhanced Delivery Oligonucleotide (EDO) Pipeline at 2021 Muscular Dystrophy Association Virtual Clinical and Scientific Conference

March 15, 2021

EDO platform demonstrates potentially best-in-class safety and efficacy profile in addressing DMD and DM1 disease phenotypes; advancing rapidly to the clinic with first-in-human studies expected to initiate in early 2022 Boston, Mass. and Oxford, UK (March 15, 2021) – PepGen, an emerging biotechnology company focused on developing transformative therapies for individuals living with neuromuscular and …

PepGen to Present Late-Breaking Data from Novel Enhanced Delivery Oligonucleotide (EDO) Pipeline at 2021 Muscular Dystrophy Association Virtual Clinical and Scientific Conference Read More »

PepGen Announces Formation of Scientific Advisory Board

February 26, 2021

World-renowned Neuromuscular Disease and Oligonucleotide experts Matthew Wood, M.D., Ph.D., Art Krieg, M.D., Elizabeth McNally, M.D., Ph.D., Charles Thornton, M.D., Jonathon Watts, Ph.D., and Brenda Wong, M.D., to join PepGen’s Scientific Advisory Board Boston, Mass. and Oxford, UK (February 26, 2021) – PepGen, an emerging biotechnology company focused on transforming the care of patients with …

PepGen Announces Formation of Scientific Advisory Board Read More »

PepGen Announces Appointment of James McArthur, Ph.D., as President and Chief Executive Officer

February 4, 2021

Seasoned biotech executive with deep experience and proven track record in successfully leading rare disease companies through rapid growth and development   Boston, Mass. and Oxford, UK (February 4th, 2021) – PepGen, a biotechnology company focused on transforming the care of patients with neuromuscular diseases through the enhanced delivery of therapeutic oligonucleotides, today announced the …

PepGen Announces Appointment of James McArthur, Ph.D., as President and Chief Executive Officer Read More »

PepGen raises $45M Series A

December 9, 2020

RA Capital Management leads $45M Series A financing for PepGen’s next-generation oligonucleotide platform targeting Duchenne muscular dystrophy and other rare neuromuscular and cardiac diseases. PepGen’s proprietary cell-penetrating peptide technology promises enhanced safety, efficacy, and improved delivery to cardiac muscle; Oxford Sciences Innovation, The University of Oxford, and CureDuchenne Ventures also participated in the Series A …

PepGen raises $45M Series A Read More »

Recent publication honoured by the OTS

October 21, 2019

A recent publication utilising the precursor technology that underpins PepGen’s platform has been awarded ‘Paper of the Month‘ by the Board of Directors and the Scientific Advisory Council of the Oligonucleotide Therapeutics Society (OTS). In addition, this publication is currently under consideration for the OTS Paper of the Year Award at the 2020 Annual Society …

Recent publication honoured by the OTS Read More »

Peptide-conjugated oligonucleotides evoke long-lasting myotonic dystrophy correction in patient-derived cells and mice

September 10, 2019

Klein et. al., The Journal of Clinical Investigation (2019), online publication ahead of print version

How much dystrophin is enough: the physiological consequences of different levels of dystrophin in the mdx mouse

September 8, 2019

Godfrey et. al., Human Molecular Genetics (2015), 24(15), 4225

Targeting RNA to treat neuromuscular disease

September 5, 2019

Muntoni and Woods, Nature Reviews Drug Discovery (2011), 10, 612

PepGen to Present Late-Breaking Data from Novel Enhanced Delivery Oligonucleotide (EDO) Pipeline at 2021 Muscular Dystrophy Association Virtual Clinical and Scientific Conference

EDO platform demonstrates potentially best-in-class safety and efficacy profile in addressing DMD and DM1 disease phenotypes; advancing rapidly to the clinic with first-in-human studies expected to initiate in early 2022 Boston, Mass. and Oxford, UK (March 15, 2021) – PepGen, an emerging biotechnology company focused on developing transformative therapies for …

Read More

PepGen Announces Formation of Scientific Advisory Board

World-renowned Neuromuscular Disease and Oligonucleotide experts Matthew Wood, M.D., Ph.D., Art Krieg, M.D., Elizabeth McNally, M.D., Ph.D., Charles Thornton, M.D., Jonathon Watts, Ph.D., and Brenda Wong, M.D., to join PepGen’s Scientific Advisory Board Boston, Mass. and Oxford, UK (February 26, 2021) – PepGen, an emerging biotechnology company focused on transforming …

Read More

PepGen Announces Appointment of James McArthur, Ph.D., as President and Chief Executive Officer

Seasoned biotech executive with deep experience and proven track record in successfully leading rare disease companies through rapid growth and development   Boston, Mass. and Oxford, UK (February 4th, 2021) – PepGen, a biotechnology company focused on transforming the care of patients with neuromuscular diseases through the enhanced delivery of …

Read More

PepGen raises $45M Series A

RA Capital Management leads $45M Series A financing for PepGen’s next-generation oligonucleotide platform targeting Duchenne muscular dystrophy and other rare neuromuscular and cardiac diseases. PepGen’s proprietary cell-penetrating peptide technology promises enhanced safety, efficacy, and improved delivery to cardiac muscle; Oxford Sciences Innovation, The University of Oxford, and CureDuchenne Ventures also …

Read More

Recent publication honoured by the OTS

A recent publication utilising the precursor technology that underpins PepGen’s platform has been awarded ‘Paper of the Month‘ by the Board of Directors and the Scientific Advisory Council of the Oligonucleotide Therapeutics Society (OTS). In addition, this publication is currently under consideration for the OTS Paper of the Year Award …

Read More

Peptide-conjugated oligonucleotides evoke long-lasting myotonic dystrophy correction in patient-derived cells and mice

Klein et. al., The Journal of Clinical Investigation (2019), online publication ahead of print version

Read More

Cell-Penetrating Peptide Conjugates of Steric Blocking Oligonucleotides as Therapeutics for Neuromuscular Diseases from a Historical Perspective to Current Prospects of Treatment

Gait et. al., Nucleic Acid Therapeutics (2018), 29(1), 1

Read More

How much dystrophin is enough: the physiological consequences of different levels of dystrophin in the mdx mouse

Godfrey et. al., Human Molecular Genetics (2015), 24(15), 4225

Read More

Pip6-PMO, A New Generation of Peptide-oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity for DMD Treatment

Betts et. al., Molecular Therapy–Nucleic Acids (2012, 1(8), e38

Read More

Targeting RNA to treat neuromuscular disease

Muntoni and Woods, Nature Reviews Drug Discovery (2011), 10, 612

Read More